A Dark Vector Cognition product

Bio-Techne 10-Q 2022-03-31

TECH · CIK 842023 · Form 10-Q · Period ended March 31, 2022 · Filed May 9, 2022

Revenue rose 19.2% to $290 million. Operating margin was 31.1%, against 28.2% a year earlier. Net income was $60.7 million.

8 sections, 136K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Mar 31, 2022Quarter ended Mar 31, 2021Change
Revenue$290M$244M+19.2%
Operating income$90.4M$68.6M+31.8%
Net income$60.7M$45.8M+32.7%
Diluted EPS$1.48$1.12+32.1%
Cash and equivalents$161Mn/an/a
Operating margin*31.1%28.2%+3.0 pts

From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.

The 49 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

​

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

​

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022**, or**

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

​

Commission file number 0-17272

BIO-TECHNE CORPORATION

(Exact name of registrant as specified in its charter)

Minnesota41-1427402
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
614 McKinley Place N.E. Minneapolis**,** MN 55413(612) 379-8854
(Address of principal executive offices) (Zip Code)(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

​

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueTECHThe NASDAQ Stock Market LLC

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b- 2). ☐ Yes ☒ No

​

At May 3, 2022, 39,233,511 shares of the Company's Common Stock (par value $0.01) were outstanding.

​

​

​

​

​

​

TABLE OF CONTENTS

​

Page
PART I. FINANCIAL INFORMATION
Item 1.Condensed Consolidated Financial Statements (Unaudited)1
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations22
Item 3.Quantitative and Qualitative Disclosures about Market Risk30
Item 4.Controls and Procedures30
PART II: OTHER INFORMATION
Item 1.Legal Proceedings31
Item 1A.Risk Factors31
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds31
Item 3.Defaults Upon Senior Securities31
Item 4.Mine Safety Disclosures31
Item 5.Other Information31
Item 6.Exhibits32
​SIGNATURES34

​

​

​

​

​

​

PART I. FINANCIAL INFORMATION

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

AND COMPREHENSIVE INCOME

Bio-Techne Corporation and Subsidiaries

(in thousands, except per share data)

(unaudited)

​

​​​​​​​​​​​​​
​Quarter Ended​Nine Months Ended
​​March 31,​March 31,
​​2022​2021​2022​2021
​​​​​​​​​​​​​
Net sales​$290,376​$243,552​$817,371​$672,004
Cost of sales​88,918​75,278​261,225​215,098
Gross margin​201,458​168,274​556,146​456,906
​​​​​​​​​​​​​
Operating expenses:​​​​
Selling, general and administrative​89,269​82,596​276,137​238,310
Research and development​21,742​17,052​63,992​49,882
Total operating expenses​111,011​99,648​340,129​288,192
Operating income​90,447​68,626​216,017​168,714
​​​​​​​​​​​​​
Other income (expense)​(21,675)​(23,272)​6,317​(27,652)
Earnings before income taxes​68,772​45,354​222,334​141,062
Income taxes (benefit)​8,628​(48)​21,150​16,121
Net earnings, including noncontrolling interest​60,144​45,402​201,184​124,941
Net earnings (loss) attributable to noncontrolling interest​(595)​(380)​(9,343)​(509)
Net earnings attributable to Bio-Techne​$60,739​$45,782​$210,527​$125,450
Other comprehensive income (loss):​​​​
Foreign currency translation adjustments​(2,851)​(1,142)​(9,573)​27,700
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8​7,179​1,288​11,745​5,490
Other comprehensive income (loss)​4,328​146​2,172​33,190
Other comprehensive income (loss) attributable to noncontrolling interest​(1)​(69)​26​14
Other comprehensive income (loss) attributable to Bio-Techne​4,329​215​2,146​33,176
Comprehensive income attributable to Bio-Techne​$65,068​$45,997​$212,673​$158,626
​​​​​​​​​​​​​
Earnings per share attributable to Bio-Techne:​​​​​​​​​​​
Basic​$1.55​$1.18​$5.36​$3.24
Diluted​$1.48​$1.12​$5.12​$3.11
​​​​​​​​​​​​​
Weighted average common shares outstanding:​​​​​
Basic​39,272​38,856​39,225​38,693
Diluted​40,969​40,676​41,073​40,305

​

See Notes to Condensed Consolidated Financial Statements.

​

CONDENSED CONSOLIDATED BALANCE SHEETS

Bio-Techne Corporation and Subsidiaries

(in thousands, except share and per share data)

​

​​​​​​​
​March 31,​​​
​​2022​June 30,
​​(unaudited)​2021
ASSETS​​
Current assets:​​
Cash and cash equivalents​$160,821​$199,091
Short-term available-for-sale investments​70,351​32,463
Accounts receivable, less allowance for doubtful accounts of $1,522 and $1,229, respectively​202,095​145,385
Inventories​128,283​116,748
Other current assets​31,558​16,919
Total current assets​593,108​510,606
​​​​​​​
Property and equipment, net​218,398​207,907
Right of use asset​63,450​73,834
Goodwill​827,618​843,067
Intangible assets, net​551,342​615,968
Other assets​45,976​11,575
Total assets​$2,299,892​$2,262,957
LIABILITIES AND SHAREHOLDERS’ EQUITY​​
Current liabilities:​​
Trade accounts payable​$30,859​$29,384
Salaries, wages and related accruals​55,642​51,294
Accrued expenses​19,998​15,282
Contract liabilities​23,107​18,995
Income taxes payable​9,788​5,336
Operating lease liabilities - current​11,864​11,602
Contingent consideration payable​—​4,000
Current portion of long-term debt obligations​12,500​12,500
Other current liabilities​3,080​3,891
Total current liabilities​166,838​152,284
​​​​​​​
Deferred income taxes​99,301​93,125
Long-term debt obligations​246,514​328,827
Long-term contingent consideration payable​4,800​25,400
Operating lease liabilities​56,348​67,625
Other long-term liabilities​12,769​24,462
Bio-Techne’s Shareholders’ equity:​​
​​​​​​​
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding​—​—
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 39,263,444 and 38,955,484, respectively​393​390
Additional paid-in capital​636,321​534,411
Retained earnings​1,132,807​1,085,461
Accumulated other comprehensive loss​(55,145)​(57,291)
Total Bio-Techne’s shareholders’ equity​1,714,376​1,562,971
Noncontrolling interest​(1,054)​8,263
Total shareholders’ equity​1,713,322​1,571,234
Total liabilities and shareholders’ equity​$2,299,892​$2,262,957

​

See Notes to Condensed Consolidated Financial Statements.

​

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Bio-Techne Corporation and Subsidiaries

(in thousands)

(unaudited)

​

​​​​​​​
​Nine Months Ended
​​March 31,
​​2022​2021
CASH FLOWS FROM OPERATING ACTIVITIES:​​
Net earnings, including noncontrolling interest​$201,184​$124,941
Adjustments to reconcile net earnings to net cash provided by operating activities:​​
Depreciation and amortization​75,203​63,075
Costs recognized on sale of acquired inventory​1,596​91
Deferred income taxes​7,888​(6,023)
Stock-based compensation expense​33,777​39,174
Contingent consideration payments - operating​(3,300)​(155)
Fair value adjustment to contingent consideration payable​(20,600)​6,188
Fair value adjustment on available for sale investments​(15,569)​10,234
Asset impairment restructuring​​546​​—

Showing the first 8K of 84K characters. Open the full section

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

The following management discussion and analysis (“MD&A”) provides information that we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative information about the material sales drivers including the effect of acquisitions and changes in foreign currency at the corporate and segment level. We also provide quantitative information about discrete tax items and other significant factors we believe are useful for understanding our results. The MD&A should be read in conjunction with both the unaudited condensed consolidated financial information and related notes included in this Form 10-Q, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended June 30, 2021. This discussion contains various “Non-GAAP Financial Measures” and also contains various “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements entitled “Non-GAAP Financial Measures” and “Forward-Looking Information and Cautionary Statements” located at the end of Item 2 of this report.

OVERVIEW

Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (Bio-Techne, we, our, us or the Company) develop, manufacture and sell biotechnology reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

Consistent with the prior year, we have operated with two segments – our Protein Sciences segment and our Diagnostics and Genomics segment – during the third quarter of fiscal 2022. Our Protein Sciences segment is a leading developer and manufacturer of high-quality purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. Our Diagnostics and Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.

RECENT ACQUISITIONS

A key component of the Company's strategy is to augment internal growth at existing businesses with complementary acquisitions. The Company did not make any acquisitions in the nine months ended March 31, 2022. As disclosed in Note 1, the Company made a $25 million investment in a forward contract, which allows the Company to acquire Wilson Wolf based on certain revenue or EBITDA thresholds being met. Refer to the prior year Annual Report on form 10-K for additional disclosure regarding the Company's recent acquisitions.

RESULTS OF OPERATIONS

Operational Update

Consolidated net sales increased 19% and 22% for the quarter and nine months ended March 31, 2022, respectively, compared to the same prior year periods. Organic growth for the quarter ended March 31, 2022 was 17% compared to the prior year, with acquisitions contributing 3% to revenue growth and foreign currency exchange having an unfavorable impact of 1%. Organic growth for the nine months ended March 31, 2022 was 18% compared to the prior year same period with acquisitions contributing 4% to revenue growth and foreign currency exchange having an immaterial impact.

Consolidated net earnings attributable to Bio-Techne increased to $60.7 million and $210.5 million for the quarter and nine months ended March 31, 2022, respectively, as compared to $45.8 million and $125.5 million in the same prior year periods. The increase in net earnings attributable to Bio-Techne for the quarter ended March 31, 2022 is primarily due to sales growth and changes in the fair value of contingent consideration for acquisitions. The increase in net earnings attributable to Bio-Techne for the nine months ended March 31, 2022 is primarily due to sales growth and changes in the fair value of contingent consideration for acquisitions, partially offset by changes in the fair value of our CCXI investment.

Business Strategy Update

Environmental

The Company’s key business strategies for long-term growth and profitability continue to be geographic expansion, core product innovation, acquisitions and talent retention and development. In fiscal 2022, the Company is also focused on evaluating how climate change impacts from our business operations might be measured and mitigated, with the plan of integrating consideration of greenhouse gas emissions and other climate variables into those key business strategies.

In response to the COVID-19 pandemic, the Company took additional steps to monitor and strengthen our supply chain to maintain an uninterrupted supply of our critical products and services. The Company has maintained these procedures while incorporating additional considerations regarding potential adverse weather events associated with climate change.

The financial impact of potential environmental regulations pertaining to carbon emissions or the integration of climate change impacts into our core business strategies are not expected to materially alter the Company’s near-term financial results. Additionally, the Company is creating a cross-functional internal council to evaluate potential long-term business impacts while driving long-term sustainability solutions.

Digital

In driving our four key business strategies, the Company utilizes digital networks and systems for data transmission, transaction processing, and storing of electronic information. As disclosed in Item 1A Risk Factors of the Company’s 10-K, increased cybersecurity attack activity poses a risk for our business. In response to this risk, the Company actively completes system patching and required maintenance, performs internal and third-party employee training, monitors network and system activity, and completes data backups for our systems. However, even with the Company’s procedures performed, our digital networks and systems are still potentially vulnerable to cyberattacks.

The financial impact of our cybersecurity initiatives and activities are ongoing and not expected to have a material impact on our financial results. However, the impact on our financial results from a material cyber breach would be unknown and dependent on the nature of the breach.

Net Sales

Consolidated net sales for the quarter and nine months ended March 31, 2022 were $290.4 million and $817.4 million, respectively, an increase of 19% and 22% from the same prior year periods. Organic growth for the quarter ended March 31, 2022 was 17% compared to the prior year, with acquisitions contributing 3% to revenue growth and foreign currency exchange having an unfavorable impact of 1%. Organic growth for the nine months ended March 31, 2022 was 18% compared to the prior year same period with acquisitions contributing 4% to revenue growth and foreign currency exchange having an immaterial impact. Organic growth for the quarter and nine months ended March 31, 2022 is primarily driven by broad based revenue growth and by overall execution of the Company's long-term growth strategy.

Gross Margins

Consolidated gross margins for the quarter and nine months ended March 31, 2022 were 69.4% and 68.0% respectively, compared to 69.1% and 68.0% for the same prior year periods. Under purchase accounting, inventory is valued at fair value less expected selling and marketing costs, resulting in reduced margins in future periods as the inventory is sold. Excluding the impact of costs recognized upon the sale of acquired inventory, stock compensation expense, amortization of intangibles, and impact of partially owned consolidated subsidiaries, adjusted gross margins for the quarter and nine months ended March 31, 2022 were 73.2% and 72.3%, respectively compared to 73.0% and 72.2% for the quarter and nine months ended March 31, 2021, respectively. Both consolidated gross margin and non-GAAP adjusted gross margins for the quarter ended March 31, 2022 were positively impacted by volume leverage and favorable product mix as compared to the prior year. Consolidated gross margin and non-GAAP adjusted gross margin for the nine months ended March 31, 2022 remained relatively consistent with the prior period due to volume leverage and product mix, partially offset by additional investments made in the business to support future growth.

​

A reconciliation of the reported consolidated gross margin percentages, adjusted for acquired inventory sold, intangible amortization, stock compensation expense, and impact of partially owned consolidated subsidiaries included in cost of sales, is as follows:

​

​​​​​​​​​​​
​Quarter Ended​​Nine Months Ended​
​​March 31,​​March 31,​
​20222021​20222021
​​​​​​​​​​​
Consolidated gross margin percentage69.4%69.1%​68.0%68.0%
Identified adjustments:​
Costs recognized upon sale of acquired inventory—%—%​0.2%0.0%
Amortization of intangibles3.5%3.6%​3.7%3.9%
Stock compensation expense - COGS​0.1%0.2%​0.1%0.2%
Impact of partially owned consolidated subsidiaries(1)0.2%0.1%​0.3%0.1%
Non-GAAP adjusted gross margin percentage73.2%73.0%​72.3%72.2%

​

(1) Adjusted gross margin percentages for the third quarter and full year of fiscal 2021 have been updated for comparability to fiscal 2022 for the inclusion of the impact of partially owned consolidated subsidiaries on the Company’s adjusted gross margin percentage.

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased 8% to $89.3 million and increased 16% to $276.1 million for the quarter and nine months ended March 31, 2022, respectively, from the same prior year periods. The increase in expense was due to strategic growth investments and the Asuragen acquisition in the fourth quarter of fiscal 2021.

Research and Development Expenses

Research and development expenses increased 28% to $21.7 million and increased 28% to $64.0 million for the quarter and nine months ended March 31, 2022, respectively, from the same prior year periods. The increase in expense was due to strategic growth investments and the Asuragen acquisition in the fourth quarter of fiscal 2021.

Segment Results

Protein Sciences

​

​​​​​​​​​​​​​​​
​Quarter Ended​​Nine Months Ended​
​​March 31,​​March 31,​
​​20222021​20222021
Net sales (in thousands)$213,176​$185,623​​$615,332​$512,248​
Operating margin percentage45.4%47.9%​45.5%46.8%

​

Protein Sciences’ net sales for the quarter and nine months ended March 31, 2022 were $213.2 million and $615.3 million, respectively, with reported growth of 15% and 20% compared to the same respective prior year periods. Organic growth for the quarter and nine months ended March 31, 2022 was 16% and 20%, respectively, when compared to the prior year. Currency exchange had a 1% unfavorable impact and an immaterial impact for the quarter and nine months ended March 31, 2022, respectively. Segment growth was driven by strong BioPharma demand resulting in broad-based growth across our proteomic research reagents and analytical tools.

The operating margin was 45.4% and 45.5% for the quarter and nine months ended March 31, 2022, respectively, compared to 47.9% and 46.8% in both comparative prior year periods. The segment’s operating margin compared to the prior year was negatively impacted by strategic investments to support future growth, which was partially offset by volume leverage.

Diagnostics and Genomics

​

​​​​​​​​​​​​​​​
​Quarter Ended​​Nine Months Ended​
​​March 31,​​March 31,​
​​20222021​20222021
Net sales (in thousands)$77,679​$58,093​​$203,191​$160,687​
Operating margin percentage25.0%17.9%​18.6%16.9%

​

Diagnostics and Genomics' net sales for the quarter and nine months ended March 31, 2022 were $77.7 million and $203.2 million, respectively, with reported growth of 34% and 26% compared to the same respective prior year periods. Organic growth for the quarter and nine months ended March 31, 2022 was 19% and 11%, respectively, when compared to the prior year. Acquisitions contributed 15% to revenue growth for both the quarter and nine months ended March 31, 2022. Currency exchange had an immaterial impact for both the quarter and nine months ended March 31, 2022. Segment growth was driven by the Asuragen acquisition in the fourth quarter of fiscal 2021 and organic growth. Organic growth was driven by an exclusive agreement entered into for development, finalization and commercialization of our ExoTRU kidney transplant rejection test and continued strength in our diagnostic reagent product lines.

The operating margin for the segment was 25.0% and 18.6% for the quarter and nine months ended March 31, 2022, respectively, compared to 17.9% and 16.9% in both comparative prior year periods. The segment’s operating margin was favorably impacted by volume leverage and product mix, which were partially offset by additional investments made in the business to support future growth for the quarter and nine months ended March 31, 2022.

Income Taxes

Income taxes were at an effective rate of 12.5% and 9.5% of consolidated earnings for the quarter and nine month period ended March 31, 2022, respectively, compared to (0.1)% and 11.4% for the same respective prior year periods. The change in the Company’s tax rate for the quarter and nine months ended March 31, 2022 was driven by the composition and amount of net income across periods and the impact of discrete tax items of $6.3 million and $31.6 million, respectively, compared to prior year discrete tax items of $11.6 million and $19.5 million as further discussed in Note 12.

The forecasted tax rate as of the third fiscal quarter of 2022 before discrete items is 23.8% compared to the prior year forecasted tax rate before discrete items of 25.2%. Excluding the impact of discrete items, the Company expects the consolidated income tax rate for the remainder of fiscal 2022 to range from 23% to 27%.

​

​

Net Earnings

​

Non-GAAP adjusted consolidated net earnings are as follows:

​

​​​​​​​​​​​​​​​
​Quarter Ended​​Nine Months Ended​
​​March 31,​​March 31,​
​​2022​2021​​2022​2021​
​​​​​​​​​​​​​​​
Net earnings before taxes - GAAP​$68,772​$45,354​​$222,334​$141,062​
Identified adjustments attributable to Bio-Techne:​​​​​​
Costs recognized upon sale of acquired inventory​—​68​​1,596​91​
Amortization of intangibles​18,173​15,222​​54,942​45,750​
Acquisition related expenses​(3,616)​1,825​​(19,046)​6,571​
Eminence impairment​​—​​—​​​18,715​​—​
Stock based compensation, inclusive of employer taxes​9,056​11,968​​37,731​41,525​
Restructuring costs​(291)​—​​1,638​142​
Investment (gain) loss and other​18,100​16,590​​(16,530)​10,232​
Impact of partially owned subsidiaries(1)​1,028​591​​3,595​798​
​​​​​​​​​​​​​​​
Non-GAAP adjusted net earnings attributable to Bio-Techne(1)​$111,222​$91,618​​$304,975​$246,171​
Non-GAAP tax rate​21.2%20.2%​21.2%20.2%
Non-GAAP tax expense​23,656​18,577​​64,732​49,551​
Non-GAAP adjusted net earnings attributable to Bio-Techne(1)​$87,566​$73,041​​$240,243​$196,620​
Earnings per share - diluted - Adjusted​$2.14​$1.80​​$5.85​$4.88​

​

(1)Adjusted consolidated net earnings and earnings per share for the third quarter and full year of fiscal 2021 have been updated for comparability to fiscal 2022 for the inclusion of the impact of partially owned consolidated subsidiaries on the Company’s adjusted consolidated net earnings and earnings per share.

Depending on the nature of discrete tax items, our reported tax rate may not be consistent on a period to period basis. The Company independently calculates a non-GAAP adjusted tax rate considering the impact of discrete items and jurisdictional mix of the identified non-GAAP adjustments. The following table summarizes the reported GAAP tax rate and the effective non-GAAP adjusted tax rate for the quarter and nine months ended March 31, 2022 and March 31, 2021.

​

​​​​​​​​​​​
​Quarter Ended​​Nine Months Ended​
​​March 31,​​March 31,​
​​2022​2021​​2022​2021​
​​​​​​​​​​​
GAAP effective tax rate12.5%(0.1)%​9.5%11.4%
Discrete items9.125.7​14.313.8
Annual forecast update​2.2​(0.4)​​—​—​
Long-term GAAP tax rate23.8%25.2%​23.8%25.2%
​​​​​​​​​​​
Rate impact items​
Stock based compensation(1.7)​(5.6)​​(1.8)​(5.6)​
Other(0.9)0.6​(0.8)0.6
Total rate impact items(2.6)%(5.0)%​(2.6)%(5.0)%
Non-GAAP adjusted tax rate(1)21.2%20.2%​21.2%20.2%

​

(1) In our third quarter results of fiscal 2021, the Company recast our first quarter results using the non-GAAP tax rate for the first nine months of fiscal 2021, which normalized the tax rate impact on adjusted earnings resulting from return to growth patterns seen prior to the onset of the COVID-19 pandemic.

The difference between the reported GAAP tax rate and non-GAAP tax rate applied to the identified non-GAAP adjustments for the quarter ended March 31, 2022 is primarily a result of discrete tax items, including the tax benefit of stock option exercises.

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents and available-for-sale investments were $231.2 million as of March 31, 2022, compared to $231.6 million as of June 30, 2021. Included in available-for-sale-investments was the fair value of the Company's investment in ChemoCentryx, Inc. (CCXI) which was $36.5 million as of March 31, 2022 and $20.0 million as of June 30, 2021. Also included in the available-for-sale-investments was the fair value of the Company’s investment in exchange traded investment grade bond funds, which was $19.4 million as of March 31, 2022. The Company did not hold these funds as of June 30, 2021.

The Company has a line-of-credit and term loan governed by a Credit Agreement dated August 1, 2018. See Note 6 to the Condensed Consolidated Financial Statements for a description of the Credit Agreement.

The Company has remaining potential contingent consideration payments of up to $105 million related to the Asuragen acquisition as of March 31, 2022. The fair value of the remaining payments is $4.8 million as of March 31, 2022.

Management of the Company expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months, through currently available cash, cash generated from operations, and remaining credit available on its existing revolving line of credit.

Cash Flows From Operating Activities

The Company generated cash of $222.6 million from operating activities in the nine months ended March 31, 2022 compared to $230.1 million in the nine months ended March 31, 2021. The decrease from the prior year was primarily due to changes in the timing of cash payments on certain operating assets and liabilities, largely offset by an increase in year over year net earnings.

Cash Flows From Investing Activities

We continue to make investments in our business, including capital expenditures.

Capital expenditures for fixed assets for the nine months ended March 31, 2022 and March 31, 2021 were $31.3 million and $33.0 million, respectively. Capital expenditures for the remainder of fiscal 2022 are expected to be approximately $23 million. Capital expenditures are expected to be financed through currently available funds and cash generated from operating activities. Expected additions in fiscal 2022 is related to increasing capacity to meet expected sales growth across the Company.

During the nine months ended March 31, 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to purchase the full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or EBITDA thresholds are met. The Company is currently forecasting the first option payment of $231 million to occur in either fiscal 2023 or fiscal 2024 with the second option payment of approximately $1 billion plus potential contingent consideration occurring between fiscal 2026 and fiscal 2028.

Cash Flows From Financing Activities

During the nine months ended March 31, 2022 and March 31, 2021, the Company paid cash dividends of $37.6 million and $37.2 million, respectively, to all common shareholders. On May 4, 2022, the Company announced the payment of a $0.32 per share cash dividend, or approximately $12.6 million, will be payable May 27, 2022 to all common shareholders of record on May 16, 2022.

Cash of $68.3 million and $55.0 million was received during the nine months ended March 31, 2022 and 2021, respectively, from the exercise of stock options.

During the nine months ended March 31, 2022 and March 31, 2021, the Company made payments of $172.4 million and $141.4 million, respectively, towards the balance of its line-of-credit facility and term loan. During the nine months ended March 31, 2022, the Company borrowed $90.0 million of its line-of-credit facility. There were no borrowings for the nine months ended March 31, 2021.

During the nine months ended March 31, 2022 and March 31, 2021, the Company repurchased $102.1 million and $43.2 million of common stock, respectively.

During the nine months ended March 31, 2022 and March 31, 2021, the Company made $23.4 million and $13.5 million in other financing payments, respectively, related to taxes paid on restricted stock units and stock options exercised through a net share settlement.

CRITICAL ACCOUNTING POLICIES

The Company's significant accounting policies are discussed in the Company's Annual Report on Form 10-K for fiscal 2021 and are incorporated herein by reference. The application of certain of these policies requires judgments and estimates that can affect the results of operations and financial position of the Company. Judgments and estimates are used for, but not limited to, valuation of available-for-sale investments, inventory valuation and allowances, valuation of intangible assets and goodwill and valuation of investments in unconsolidated entities. There have been no significant changes in estimates in the quarter or nine months ended March 31, 2022 that would require disclosure nor have there been any changes to the Company's policies.

NON-GAAP FINANCIAL MEASURES

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Item 2, contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:

●Organic Growth

●Adjusted gross margin

●Adjusted net earnings

●Adjusted effective tax rate

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP financial measure of organic growth represents revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, as well as the impact of partially owned consolidated subsidiaries. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from partially owned subsidiaries consolidated in our financial statements are also excluded from our organic revenue calculation, as those revenues are not fully attributable to the Company. Revenue from partially owned subsidiaries was $0.7 million and $1.6 million for the quarter and nine months ended March, 31, 2022, respectively.

Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including non-recurring costs, goodwill and long-lived asset impairments, and gains. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjection assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory and acquisition-related expenses inclusive of the changes in fair value contingent consideration, and other non-recurring items including gains or losses on legal settlements, goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to partially owned consolidated subsidiaries in the calculation of our non-GAAP financial measures as the revenues and expenses are not fully attributable to the Company.

The Company’s non-GAAP adjusted operating margin and adjusted net earnings, in total and on a per share basis, also excludes stock-based compensation expense, which is inclusive of the employer portion of payroll taxes on those stock awards, restructuring, impairments of equity method investments, gain and losses from investments, and certain adjustments to income tax expense. Impairments of equity investments are excluded as they are not part of our day-to-day operating decisions. Additionally, gains and losses from other investments that are either isolated or cannot be expected to occur again with any predictability are excluded. Costs related to restructuring activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.

The Company periodically reassesses the components of our non-GAAP adjustments for changes in how we evaluate our performance, changes in how we make financial and operational decisions, and considers the use of these measures by our competitors and peers to ensure the adjustments are still relevant and meaningful.

Readers are encouraged to review the reconciliations of the adjusted financial measures used in management's discussion and analysis of the financial condition of the Company to their most directly comparable GAAP financial measures provided within the Company's consolidated financial statements.

FORWARD LOOKING INFORMATION AND CAUTIONARY STATEMENTS

This quarterly report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those regarding the Company's expectations as to the effect of changes to accounting policies, the amount of capital expenditures for the remainder of the fiscal year, the source of funding for capital expenditure requirements, the sufficiency of currently available funds for meeting the Company's needs, the impact of fluctuations in foreign currency exchange rates, and expectations regarding gross margin fluctuations, increasing research and development expenses, increasing selling, general and administrative expenses and income tax rates. These statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: integration of newly acquired businesses, the introduction and acceptance of new products, general national and international economic, political, regulatory, and other conditions, increased competition, the reliance on internal manufacturing and related operations, the impact of currency exchange rate fluctuations, the recruitment and retention of qualified personnel, the impact of governmental regulation, maintenance of intellectual property rights, credit risk and fluctuation in the market value of the Company's investment portfolio, and unseen delays and expenses related to facility construction and improvements. For additional information concerning such factors, see the Company's Annual Report on Form 10-K for fiscal 2021 as filed with the Securities and Exchange Commission and Part II. Item 1A below.

​

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As of March 31, 2022, the Company held an investment in the common stock of CCXI. The investment was included in short-term available-for-sale investments at its fair value of $36.5 million. The Company also holds exchange traded investment grade bond funds, which is included in short-term available-for-sale investments at its fair value of $19.4 million. As of March 31, 2022, the potential loss in fair value due to a 10% decrease in the market value of CCXI and the exchange traded investment grade bond funds was $3.7 million and $1.9 million, respectively.

The Company operates internationally, and thus is subject to potentially adverse movements in foreign currency exchange rates. For the quarter ended March 31, 2022, approximately 33% of consolidated net sales were made in foreign currencies, including 11% in euros, 4% in British pound sterling, 6% in Chinese yuan and the remaining 12% in other currencies. The Company is exposed to market risk mainly from foreign exchange rate fluctuations of the euro, British pound sterling, the Chinese yuan, and the Canadian dollar, as compared to the U.S. dollar as the financial position and operating results of the Company's foreign operations are translated into U.S. dollars for consolidation.

Month-end average exchange rates between the British pound sterling, euro, Chinese yuan and Canadian dollar, which have not been weighted for actual sales volume in the applicable months in the periods, to the U.S. dollar were as follows:

​

​​​​​​​​​​​​​
​Quarter Ended​Nine Months Ended
​​March 31,​March 31,
​​2022​2021​2022​2021
Euro$1.12$1.20​$1.15$1.19
British pound sterling​1.34​1.38​1.36​1.33
Chinese yuan​0.16​0.15​0.16​0.15
Canadian dollar​0.79​0.79​0.79​0.77

​

The Company's exposure to foreign exchange rate fluctuations also arises from trade receivables, trade payables and intercompany payables denominated in one currency in the financial statements, but receivable or payable in another currency. The effects of a hypothetical simultaneous 10% appreciation in the U.S. dollar from March 31, 2022 levels against the euro, British pound sterling, Chinese yuan and Canadian dollar are as follows (in thousands):

​

​​​​
Decrease in translation of earnings of foreign subsidiaries (annualized)$4,227
Decrease in translation of net assets of foreign subsidiaries​80,143
Additional transaction losses​3,128

​

​

​

Item 4. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures.

The Company maintains disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). The Company's management has evaluated, with the participation of its Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of its disclosure controls and procedures as of the end of the period covered in this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2022, our disclosure controls and procedures were effective.

(b) Changes in internal controls over financial reporting.

There were no changes in the Company's internal control over financial reporting during the third quarter of fiscal 2022 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

As of May 9, 2022, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company's business, results of operations, financial condition or cash flows.

​

Item 1A. RISK FACTORS

During the quarter and nine months ended March 31, 2022, there have been no material changes from the risk factors found in Part I, Item 1A, "Risk Factors," of the Company's Annual Report on Form 10-K for the year ended June 30, 2021.

​

​

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The Company's previous share repurchase plan, implemented in fiscal 2019, granted management the discretion to mitigate the dilutive effect of stock option exercises for fiscal 2018, which then increases in each period subsequent to June 30, 2018 for additional dilutive impacts of stock options exercised in those future periods. On February 2, 2022, the Company replaced the prior share repurchase plan with a new share repurchase plan that authorizes the Company to purchase up to $400 million in stock. The Company repurchased 89,238 shares for $41.3 million in fiscal 2022 under the previous plan. The Company repurchased 145,000 shares for $60.8 million in fiscal 2022 under the new share repurchase plan. As of March 31, 2022, the Company had $339.2 million available to repurchase under our existing plan.

​

​​​​​​​
Period​Total Number of Shares Purchased​Average Price Paid per Share​Cash Paid (thousands)
November 1-30, 2021900​468.90422
December 1-31, 2021​88,338​462.67​40,872
January 1-31, 2022​-​-​-
February 1-28, 2022​145,000​419.57​60,838

​

​

​

ITEM 3. DEFAULT ON SENIOR SECURITIES

None.

​

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

​

Item 5. OTHER INFORMATION

None.

​

Item 6. EXHIBITS

EXHIBIT INDEX

TO

FORM 10-Q

BIO-TECHNE CORPORATION

​

​ ​​
Exhibit NumberDescription
3.1​Amended and Restated Articles of Incorporation of the Company--incorporated by reference to Exhibit 3.1 of the Company's Form 10-Q dated February 9, 2015*
​
3.2​Fourth Amended and Restated Bylaws of the Company--incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K dated April 27, 2022*
​
4.1​Description of Capital Stock -- incorporated by reference to Exhibit 4.1 of the Company's Form 10-K dated August 25, 2021*
​
10.1**​Management Incentive Plan--incorporated by reference to Exhibit 10.13 of the Company's Form 10-K for the year ended June 30, 2013*
​
10.2**​Bio-Techne 2020 Equity Incentive Plan - incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated November 3, 2020*
​
10.3**​Form of Time Vesting Restricted Stock Award Agreement - incorporated by reference to Exhibit 10.3 of the Company's Form 10-K dated August 25, 2021*
​
10.4**​Form of Performance Vesting Restricted Stock Unit Award Agreement - incorporated by reference to Exhibit 10.4 of the Company's Form 10-K dated August 25, 2021*
​
10.5**​Form of Time Vesting Restricted Stock Unit Award Agreement - incorporated by reference to Exhibit 10.5 of the Company's Form 10-K dated August 25, 2021*
​
10.6**​Form of Performance Vesting Restricted Stock Unit Award Agreement - incorporated by reference to Exhibit 10.6 of the Company's Form 10-K dated August 25, 2021*
​
10.7**​Form of the Time Vesting Performance Unit Award Agreement - incorporated by reference to Exhibit 10.7 of the Company's Form 10-K dated August 25, 2021*
​
10.8**​Form of Performance Vesting Performance Unit Award Agreement - incorporated by reference to Exhibit 10.8 of the Company's Form 10-K dated August 25, 2021*
​
10.9**​Form of Time Vesting Incentive Stock Option Agreement - incorporated by reference to Exhibit 10.9 of the Company's Form 10-K dated August 25, 2021*

​

​

​ ​​
Exhibit NumberDescription
10.10**​Form of Performance Vesting Incentive Stock Option Agreement - incorporated by reference to Exhibit 10.10 of the Company's Form 10-K dated August 25, 2021*
​
10.11**​Form of Employee Non-Qualified Stock Option Agreement - incorporated by reference to Exhibit 10.11 of the Company's Form 10-K dated August 25, 2021*
​
10.12**​Form of Director Non-Qualified Stock Option Agreement for Second Amendment and Restated 2010 Equity Incentive Plan - incorporated by reference to Exhibit 10.2 of the Company's Form 8-K dated October 26, 2017*
​
10.13**​Employment Agreement by and between the Company and Charles Kummeth - incorporated by reference to Exhibit 10.11 of the Company's Form-K dated September 7, 2017*
​
10.14**​Form of Employment Agreement by and between the Company and Executive Officers of the Company other than the CEO --incorporated by reference to Exhibit 10.12 of the Company's Form 10-K dated September 7, 2017*
​
10.15**​Form of Amendment No. 1 to Executive Employment Agreement – incorporated by reference to Exhibit 10.15 of the Company’s Form 10-Q dated May 11, 2020*
​
10.16​Credit Agreement by and among the Company, the Guarantors party thereto, the Lenders party thereto, and BMO Harris Bank N.A., as Administrative Agent, dated August 1, 2018--incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated August 2, 2018*
​
10.17**​Form of Indemnification Agreement entered into with each director and executive officer of the Company - incorporated by reference to Exhibit 10.1 of the Company's Form 10-Q dated February 8, 2018*
​
10.18**​Employment Agreement by and between the Company and Mr. William Geist dated December 20, 2021 – incorporated by reference to Exhibit 10.18 of the Company’s Form 10-Q dated February 7, 2022*
​
21​Subsidiaries of the Company - incorporated by reference to Exhibit 21 of the Company's Form 10-K dated August 25, 2021*
​
31.1​Certificate of Chief Executive Officer pursuant to section 302 of the Sarbanes Oxley Act of 2002
​
31.2​Certificate of Chief Financial Officer pursuant to section 302 of the Sarbanes Oxley Act of 2002
​
32.1​Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes Oxley Act of 2002
​
32.2​Certification of Chief Financial Officer pursuant to section 906 of the Sarbanes Oxley Act of 2002
​
101​The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter and nine months ended March 31, 2022, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Earnings and Comprehensive Income, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) Notes to the Condensed Consolidated Financial Statements.
​
104​Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
  • Incorporated by reference; SEC File No. 000-17272

** Management contract or compensatory plan or arrangement

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

​​​
​BIO-TECHNE CORPORATION
​​(Company)
​​​
Date: May 9, 2022​/s/ Charles R. Kummeth
​​Charles R. Kummeth
​​Principal Executive Officer
​​​
Date: May 9, 2022​/s/ James Hippel
​​James Hippel
​​Principal Financial Officer

​

​

​

​